Invivyd: Positive Initial Results for the Prevention of COVID-19

 

• VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants
• Data supportive of an immunobridging approach to the EVADE study of adintrevimab
• Overall favorable safety and tolerability profile of VYD222 including no study drug-related serious adverse events (SAEs) to date
• VYD222 demonstrates continued in-vitro neutralization activity against major SARS-CoV-2 variants, including against HV.1, the currently dominant variant in the U.S.   

https://www.globenewswire.com/news-release/2023/12/18/2797666/0/en/Invivyd-Announces-Positive-Initial-Results-from-Ongoing-CANOPY-Phase-3-Pivotal-Clinical-Trial-Investigating-VYD222-for-the-Prevention-of-COVID-19.html